Bide Pharmatech Co., Ltd. (SHA:688073)
China · Delayed Price · Currency is CNY 47.86
+1.17 (2.51%)
Jul 29, 2026, 4:00 PM EDT
Bide Pharmatech Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,351 | 1,324 | 1,102 | 1,092 | 833.83 | 606.22 |
Revenue Growth | 18.93% | 20.13% | 0.93% | 30.95% | 37.55% | 54.86% |
Gross Profit Gross Profit Growth | 577.11 | 550.48 | 421.66 | 418.48 | 362.54 | 290.33 |
Operating Income Operating Income Growth | 216.24 | 187.67 | 112.99 | 99.3 | 144.34 | 107.58 |
Net Income Net Income Growth | 167.88 | 151.74 | 117.43 | 109.57 | 145.97 | 97.57 |
Earnings Per Share EPS Growth | 1.93 | 1.73 | 1.32 | 1.21 | 1.98 | 1.46 |
EPS Growth | 41.08% | 31.06% | 9.09% | -38.89% | 35.89% | 53.38% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
China China Growth | 564.53 |
Overseas Overseas Growth | 759.27 |
Total Total Growth | 1,324 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,078 | 1,041 | 1,181 | 1,274 | 1,510 | 193.46 |
Total Debt Total Debt Growth | 135.42 | 141.07 | 82.2 | 57.3 | 40.82 | 27.78 |
Net Cash (Debt) Net Cash Growth | 943.08 | 900.41 | 1,099 | 1,217 | 1,469 | 165.68 |
Net Cash Growth | 205.24% | -18.04% | -9.72% | -17.17% | 786.71% | 40.92% |
Net Cash Per Share Net Cash Per Share Growth | 10.86 | 10.27 | 12.35 | 13.44 | 19.93 | 2.47 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 60.66 | 28.32 | 158.31 | -57.39 | 29.87 | -64.88 |
Capital Expenditures CapEx Growth | -25.13 | -24.28 | -88.35 | -61.08 | -38.41 | -29.2 |
Free Cash Flow Free Cash Flow Growth | 35.52 | 4.04 | 69.97 | -118.47 | -8.54 | -94.09 |
Free Cash Flow Growth | 17.30% | -94.23% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 42.73% | 41.58% | 38.26% | 38.33% | 43.48% | 47.89% |
Operating Margin | 16.01% | 14.18% | 10.25% | 9.09% | 17.31% | 17.75% |
Pretax Margin | 15.80% | 14.76% | 13.43% | 11.54% | 20.60% | 18.90% |
Profit Margin | 12.43% | 11.46% | 10.66% | 10.04% | 17.51% | 16.10% |
FCF Margin | 2.63% | 0.30% | 6.35% | -10.85% | -1.02% | -15.52% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 1.160 | 1.160 | 0.900 | 0.900 | 1.100 |
Dividend Per Share Growth | 28.89% | 28.89% | 0% | -18.18% | - |
Dividend Yield | 2.48% | 1.95% | 1.92% | 1.75% | 2.04% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.75 | 34.66 | 36.98 | 46.03 | 36.53 | - |
Forward PE | - | 27.56 | 31.74 | 22.50 | 30.12 | - |
P/FCF Ratio | 116.07 | 1301.79 | 62.06 | - | - | - |
PS Ratio | 3.05 | 3.97 | 3.94 | 4.62 | 6.40 | - |